Results 101 to 110 of about 53,202 (260)

Real-World Utilization and Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists Dosed Weekly and Daily in Patients with Type 2 Diabetes Mellitus: Results from Retrospective Electronic Medical Records in China

Diabetes, Metabolic Syndrome and Obesity
Zhen Ruan,1,* Xianwen Chen,1,* Menghuan Song,1 Ruxu Jia,2 Hang Luo,3 Carolina Oi Lam Ung,1,4,5 Hao Hu1,4,5 1State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, Macau SAR,
Ruan Z, Chen X, Song M, Jia R, Luo H, Ung COL, Hu H   +6 more
doaj  

Impact of monotherapy and combination therapy with glucagon-like peptide-1 receptor agonists on exosomal and non-exosomal MicroRNA signatures in type 2 diabetes mellitus: a systematic review

Journal of Translational Medicine
Background Glucagon-like peptide-1 receptor agonist (GLP-1RAs) is a potent therapy for type 2 diabetes mellitus (T2DM) and obesity, especially in patients who are resistant to long-term insulin therapy.
Haifeng Yu, Maryam Davoudi, Sahar Sadegh-Nejadi, Xiaolei Miao, Molood Bagherieh, Reza Afrisham   +5 more
doaj   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications

The Journal of Clinical Investigation
GLP-1 receptor agonist (GLP-1RA) medications have transformed the treatment of type 2 diabetes (T2D) and obesity, with robust evidence for cardiovascular and renal benefits.
Ryan J. Jalleh, Nicholas J. Talley, Michael Horowitz, Michael A. Nauck   +3 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP

Drug Design, Development and Therapy, 2023
Ping Fang,1 Zhengqin Ye,1 Ran Li,1 Dunmin She,2 Guannan Zong,1 Liya Zhang,1 Ying Xue,1 Keqin Zhang1 1Department of Endocrinology and Metabolism, Tongji Hospital, School of Medicine, Tongji University, Shanghai, 200065, People’s Republic of China ...
Fang P, Ye Z, Li R, She D, Zong G, Zhang L, Xue Y, Zhang K   +7 more
doaj  

Use of glucagon‐like peptide‐1 receptor agonists is associated with inadequate bowel preparation for colonoscopy in patients with diabetes

Journal of Diabetes Investigation, EarlyView.
In Japanese patients with diabetes undergoing colonoscopy, GLP‐1RA use was associated with a higher rate of inadequate bowel preparation after propensity score matching. Weekly formulations showed a higher rate than daily formulations, while additional adjusted analyses were directionally consistent but not statistically significant.
Osamu Ogawa
wiley   +1 more source

Association of GLP‐1 Receptor Agonists With Gastrointestinal and Liver Outcomes in Adults With Type 2 Diabetes: A Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Dazheng Zhang, Ying Lu, Xinyao Jian, Haoyuan Wang, Jacquelyn Hatch‐Stein, Ronen Stein, Jennifer Panganiban, Yong Chen   +7 more
wiley   +1 more source

Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Type 1 diabetes is defined by immune‐mediated beta‐cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension ...
Zachary Bloomgarden
wiley   +1 more source

Improved Glucagon Sensitivity Following Weight Loss: A Systematic Review and Meta‐Analysis

Obesity Reviews, EarlyView.
ABSTRACT Objective This systematic review and meta‐analysis investigated the effect of weight loss in people with obesity on two biomarkers of glucagon resistance: fasting plasma glucagon and alanine. Methods A comprehensive search was conducted in Medline and Embase. Random‐effects meta‐analyses and correlation analyses were performed.
Hye‐Rin Charlotte Kim, Lima Hamidi, Anne Majumdar, Matyas Fehervari, Emma Rose McGlone   +4 more
wiley   +1 more source

Baseline characteristics of type 2 diabetes patients who initiated GLP-1 receptor agonists (GLP-1RAs) or other non-GLP-1RA anti-diabetic drugs (Control) between January 2011 and March 2014 in primary care in Germany.

, 2016
Baseline characteristics of type 2 diabetes patients who initiated GLP-1 receptor agonists (GLP-1RAs) or other non-GLP-1RA anti-diabetic drugs (Control) between January 2011 and March 2014 in primary care in Germany.
Qing Qiao (439493), Karel Kostev (2577346), Susan Grandy (63301), Josh Hiller (2577343)   +3 more
core   +1 more source